ZYTO Corp. Hits New Record for Bio-technology Sales.

OREM, Utah -- ZYTO Corp. (Pink Sheets:ZYTC) has achieved another new sales record for the month of July, it was announced by company officials.

July was another record month for sales with an increase of more than $100,000 over the previous record. Company founder and C.E.O. Dr. Vaughn R. Cook says the trend will continue well into the future as the company enters into additional strategic marketing agreements.

The company has entered into a joint marketing agreement with key nutriceutical companies, referred to by ZYTO(tm) as SAMs (Strategic Alliance Members). Each SAM is able to offer ZYTO technology to the healthcare professionals who are their customers. Each healthcare professional is trained by ZYTO to use the technology to provide better clinical services to their patients or clients, which results in higher sales for the SAMs.

"It is a win, win situation for everyone. Each of these companies allow us to market our technology to their customers, who in turn use ZYTO technology to make more nutriceutical sales for the SAMs," said Cook.

Cook received a patent pending on the technology that enables computers and human bodies to communicate. Health practitioners are able to make better-informed diagnostic and clinical decisions using the ZYTO technology.

"Most healthcare practitioners who take advantage of the SAM opportunity discover that our technology is an indispensable addition to their practice. We continue to enter into more marketing agreements with additional companies, which is why we expect that the trend of increasing sales will continue," explained Cook.

The company has a web site at http://www.ZYTO.com.

About ZYTO Corp.

ZYTO Corp. provides computerized bio-technology equipment and software with clinical applications that include obtaining information from the human body to assist healthcare practitioners to make better decisions.

Forward Looking Statement:

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports the Company may file.